Research Topics
| Wendy A GattisSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Overview of current noninodilator therapies for acute heart failure syndromesWendy Gattis Stough
Duke University Medical Center, Durham, North Carolina, USA
Am J Cardiol 96:41G-6G. 2005....- Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failureWendy A Gattis
Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
Am J Cardiol 93:74B-6B. 2004..2% vs 73.4%, respectively). Based on the study's results, predischarge initiation may be a successful strategy to improve the use of beta-blocker therapy for patients with heart failure... - Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial)Wendy A Gattis
Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt Street, Box 17969, Durham, NC 27710, USA
Am J Cardiol 93:1436-7, A10. 2004..One hundred ninety-two patients were enrolled in this study. Patients with baseline cTnI values were included in this analysis, and the relation between cTnI and the composite clinical primary end point of RITZ-4 was evaluated... - Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failureWendy A Gattis
Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
Am J Cardiol 91:169-74. 2003..These results also suggest that caution should be taken when withdrawing beta blockade in this population... - Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)Wendy A Gattis
Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
J Am Coll Cardiol 41:1452-7. 2003..Tezosentan did not demonstrate pro-ischemic effects in this population. Symptomatic hypotension may have resulted in an increased number of adverse events in the treatment group. Further studies with lower tezosentan doses are warranted... - Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trialMihai Gheorghiade
Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
JAMA 291:1963-71. 2004..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function... - Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)CHRISTOPHER M O'CONNOR
Duke University Medical Center and Duke Clinical Research Institute, Durham, University of North Carolina, Chapel Hill, NC 27705, USA
Am Heart J 144:583-8. 2002..Tezosentan is a dual endothelin receptor antagonist, and it has improved cardiac output and reduced pulmonary and systemic vascular resistance in experimental animal models and in initial human acute decompensated heart failure studies... - Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trialWendy A Gattis
Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
J Am Coll Cardiol 43:1534-41. 2004..Predischarge initiation may be one approach to improve beta-blocker use in this population... - Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failureG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Am J Cardiol 92:625-8. 2003..Lower baseline hemoglobin is associated with risk of short-term adverse clinical outcomes in this population, even after controlling for other baseline differences... - The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implicationsWendy A Gattis
Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA
Rev Cardiovasc Med 3:S48-54. 2002..The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality... - Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)Wendy A Gattis
Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 145:S58-9. 2003 - Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF)Mihai Gheorghiade
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
Am Heart J 145:S55-7. 2003 - Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysisMichael P Hudson
Duke Clinical Research Institute, Durham, NC, USA
Am Heart J 147:546-52. 2004..We assessed whether elevated TnT levels are associated with the severity, etiology, and prognosis of HF in stable, ambulatory patients... - Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failureKaren E Joynt
Department of Medicine Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
Am J Cardiol 93:783-5. 2004..Baseline angiotensin-converting enzyme inhibitor plus beta-blocker use were associated with lower levels of CRP; no relation was found between CRP levels and aspirin or statin use... - Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failureMihai Gheorghiade
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
Am Heart J 145:S51-4. 2003 - Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging studyLiviu Klein
Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Am J Cardiol 93:44A-46A. 2004.... - Anemia as a risk factor and therapeutic target in heart failureG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
J Am Coll Cardiol 44:959-66. 2004..Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF... - Racial differences in the outcomes of patients with diastolic heart failureMark A East
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 148:151-6. 2004..These results are important because of the prevalence of this condition in African American patients and their potential heterogeneous response to many heart failure therapies... - Treatment gaps in the pharmacologic management of heart failureMihai Gheorghiade
Division of Cardiology, Northwestern University, Chicago, Illinois, USA
Rev Cardiovasc Med 3:S11-9. 2002..Other tools may also be considered, and testing the influence of such tools on the implementation of optimal therapy may help the scientific community better understand the factors that influence decision-making among clinicians... - Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failureWendy A Gattis
Duke University Medical Center, Durham, NC 27705, USA
Am Heart J 145:S47-50. 2003 - OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalizationMihai Gheorghiade
Division of Cardiology, Northwestern University Medical School, 201 E. Huron Street, Galter 10-240, Chicago, IL 60611, USA
Eur J Heart Fail 5:9-12. 2003 - Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and designGregg C Fonarow
Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
Am Heart J 148:43-51. 2004..The ultimate aim of this program is to improve the standard of HF care in the hospital and outpatient settings and increase the use of evidence-based therapeutic strategies to save lives... - Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysisKirkwood F Adams
Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27517, USA
J Am Coll Cardiol 46:497-504. 2005..The purpose of this study was to investigate the relationship of serum digoxin concentration (SDC) and outcomes in women with heart failure (HF)... - Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerationsLiviu Klein
Advocate Illinois Masonic Medical Center, Chicago, Illinois 60607, USA
Am J Cardiol 91:18F-40F. 2003..Finally, anticoagulation is recommended only in patients who have concomitant atrial fibrillation or a previous history of cerebral or systemic emboli... - Surrogate end points in heart failure trialsMihai Gheorghiade
Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
Am Heart J 145:S67-70. 2003 - Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trialManuela Zampino
Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
Am Heart J 145:S62-6. 2003 - Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) studyMihai Gheorghiade
Northwestern University, Feinberg School of Medicine, Chicago, Ill, USA
Am Heart J 145:S60-1. 2003 - Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalizationParag Jain
Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
Am Heart J 145:S3-17. 2003 - Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry Victor L Serebruany
Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
Pathophysiol Haemost Thromb 32:8-15. 2002..Taken together, opposite to our expectations, major clinical characteristics of heart failure did not correlate well with the platelet characteristics investigated in this study... - Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?Paul A Gurbel
Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
Am Heart J 143:1068-75. 2002..We sought to determine whether platelet activity in patients with heart failure is related to an ischemic versus nonischemic etiologic condition, clinical disease severity, or adverse clinical outcomes... - Beta-adrenergic blockers in chronic congestive heart failureWendy A Gattis
Am J Health Syst Pharm 59:467-9. 2002